Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2Phase 3 Interventional Results available

Assessment of Mechanisms of Improved Wound Healing

NCT00673309
Conditions
Burns
Interventions
Stable Isotope Infusion study, Insulin High Dose, oxandrolone, Propranolol, Growth Hormone, Insulin Low Dose, IGF-1/IGFBP-3, Itraconazole, Growth Hormone and Propranolol, Oxandrolone and Propranolol, Placebo or Control
Procedure · Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 90 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Galveston, Texas
Completed Early Phase 1 Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus

NCT00829699
Conditions
Type 2 Diabetes
Interventions
euinsulinemic euglycemic glucose clamp, euinsulinemic hyperglycemic glucose clamp, Hyperinsulinemic euglycemic glucose clamp, Hyperinsulinemic hyperglycemic glucose clamp
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Obesity, Insulin Resistance, Insulin Sensitivity, Beta-Cell Dysfunction, Prediabetes
Interventions
Placebo, Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d), High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Critical Illness, Hyperglycemia
Interventions
Serum Lab testing
Other
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
2 Years to 12 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Type 2 Diabetes Mellitus
Interventions
Active Comparator: Omnipod M System with lower starting dose, Active Comparator: Omnipod M System with higher starting dose
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
Conditions
Diabetes Mellitus, Type 2
Interventions
U-500R
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Hyperglycemia
Interventions
Resistant Starch Type 4-Raw, Resistant Starch Type 4-Cooked, Shredded Wheat
Dietary Supplement
Lead sponsor
Kansas State University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Manhattan, Kansas
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
39
States / cities
Montgomery, Alabama • Concord, California • Fresno, California + 33 more
Conditions
Poor Glycemic Control
Interventions
Metformin, Glargine insulin, Glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Obesity, Insulin Resistance, Vitamin D Deficiency
Interventions
Vitamin D3
Drug
Lead sponsor
Perrin C White, MD
Other
Eligibility
6 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Metabolism
Interventions
Overnight Metabolic Flexibility, Clamp Metabolic Flexibility
Procedure
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Not applicable Interventional Results available

Inpatient Closed-loop Glucose Control

NCT01819844
Conditions
Diabetes Mellitus, Hyperglycemia
Interventions
Closed-loop blood glucose control
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 2 Diabetes
Interventions
Placebo, Survodutide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
89
States / cities
Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 81 more
Completed Phase 4 Interventional Results available

Inpatient Diabetes on Corticosteroids

NCT01970241
Conditions
Diabetes Mellitus
Interventions
NPH, Correction Factor
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
Interventions
YG1699, Dapagliflozin
Drug
Lead sponsor
Youngene Therapeutics Inc., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Dyslipidemia
Interventions
Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 10 more
Conditions
Prediabetes, Healthy (Controls)
Interventions
Ketone Monoester (KE), Placebo
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama
Conditions
Post-Prandial Hyperglycemia, Post-Prandial Hypoglycemia
Interventions
DiAS, Afrezza low dose, Afrezza high dose
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Prebiotic Sodas on Satiety and Metabolic Responses in Healthy Men

NCT07105826
Conditions
Olipop, Poppi, Coca Cola - Classic, Diet Coke
Interventions
Prebiotic Soda 1, Prebiotic Soda 2, Diet Soda, Regular Coke
Other
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Glucose, High Blood
Interventions
Human Insulin, Finger-actuated, Metered Pump Sprayer
Biological · Device
Lead sponsor
Transdermal Delivery Solutions Corp
Industry
Eligibility
25 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Palm Beach Gardens, Florida
Conditions
Type 1 Diabetes
Interventions
Muscle Biopsy, Jell-O with Amino acids, Dextrose
Procedure · Other · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Rochester, Minnesota